Company news

Context Therapeutics Inc. news in 2023

Context Therapeutics Inc.'s news releases, calls and decks from 2023, newest first.

View company

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

November 8, 2023

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

October 30, 2023

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 26, 2023

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

August 8, 2023

Context Therapeutics to Participate in Two August 2023 Investor Conferences

July 31, 2023

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

May 9, 2023

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

March 21, 2023

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 14, 2023

Context Therapeutics announces positive responses in Phase 2 OATH clinical trial

February 6, 2023

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

February 5, 2023

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

January 8, 2023

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

January 3, 2023

Decks in 2023